|
Spontaneous abortion
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Gene expression in cultured endometrium from women with different outcomes following IVF.
|
18539642 |
2008 |
|
Abortion, Tubal
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Gene expression in cultured endometrium from women with different outcomes following IVF.
|
18539642 |
2008 |
|
Early Pregnancy Loss
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Gene expression in cultured endometrium from women with different outcomes following IVF.
|
18539642 |
2008 |
|
Miscarriage
|
0.300 |
Biomarker
|
disease |
CTD_human |
Gene expression in cultured endometrium from women with different outcomes following IVF.
|
18539642 |
2008 |
|
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We found mutations encoding L640I and A643T in the B3 domain of human CEACAM5 in colorectal adenocarcinomas; structural studies indicated that these mutations would alter the interaction between CEACAM5 and TGFBR1.
|
31585122 |
2020 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The detection of carcinoembryonic antigen (CEA)-related cell adhesion molecules 5 (CEACAM5) is significant in cancer prewarning.
|
31829549 |
2020 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The serum B7-H3, B7-H1, cancer-associated carbohydrate antigen-50 (CA-50) and carcinoembryonic antigen (CEA) expressions in patients with CRC, benign gastrointestinal diseases, and healthy controls were measured by ELISA.
|
31424670 |
2020 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Multivariate analysis of PC revealed that T4 cancer (OR 5.143, 95% CI 1.400-18.897, p = 0.014), T3 mucinous cancer (OR 17.480, 95% CI 1.577-193.714, p = 0.020), obstructed tumors (OR 6.030, 95% CI 1.627-22.343, p = 0.007), and peritoneal fluid CEA above 5 ng/dl (OR 4.073, 95% CI 1.315-12.615, p = 0.015) were significant risk factors.
|
31802190 |
2020 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Generally, serum CEA levels have not been used as tumor markers for salivary gland malignancies; however, it may be useful for MAC arising from salivary glands.
|
31828452 |
2020 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Alpha-fetoprotein (AFP), cancer antigens 15.3, 19.9, and 125, carcinoembryonic antigen, and alkaline phosphatase (ALP) are widely measured in attempts to detect cancer and to monitor treatment response.
|
31666285 |
2020 |
|
Malignant tumor of colon
|
0.100 |
Biomarker
|
disease |
BEFREE |
Combined application of PLR, HPR, and CEA may improve the diagnostic efficacy of distinguishing between colon cancer and benign colon tumors.
|
31809747 |
2020 |
|
Malignant tumor of colon
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Recently, a large-scale study on colon cancer revealed that "preoperatively elevated and postoperatively normalized CEA levels" is not an indicator of poor prognosis.
|
31799750 |
2020 |
|
Rectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prognosis after resection of rectal cancer was worse in patients with preoperatively elevated and postoperatively normalized CEA compared to those with normal preoperative CEA.
|
31799750 |
2020 |
|
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Squamous cell carcinoma antigen (SCC-Ag) and carcinoembryonic antigen (CEA) are widely used in clinical practice to predict the prognosis of patients with esophageal squamous cell carcinoma (ESCC).
|
31650302 |
2020 |
|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Computed tomography (CT)-reported T stage, CT-reported LN status, preoperative tumour differentiation, carcinoembryonic antigen, carbohydrate antigen 19-9 and TSP were independent predictors of LN metastasis in CRC.
|
31787749 |
2020 |
|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therefore, we recommend routinely performing ascites CEA analysis in colorectal cancer surgery.
|
31802190 |
2020 |
|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The serum B7-H3, B7-H1, cancer-associated carbohydrate antigen-50 (CA-50) and carcinoembryonic antigen (CEA) expressions in patients with CRC, benign gastrointestinal diseases, and healthy controls were measured by ELISA.
|
31424670 |
2020 |
|
Neoplasm Metastasis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
CEA has been shown to have surprisingly diverse functions in cell adhesion, intracellular and intercellular signaling, and complex biological processes such as cancer progression, inflammation, angiogenesis, and metastasis.
|
31828452 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The rapid quantitative tumor marker sensing of carcinoembryonic antigen in human serum samples from less than 10 ng/mL to more than 87 ng/mL is achieved, which demonstrates good agreement with the conventional chemiluminescence immunoassay system and sufficiently covers the threshold tumor marker concentration of 20 ng/mL for early cancer prediction.
|
31791874 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We aimed to find out the prognosis of stage IB invasive lung adenocarcinoma according to perioperative tumor markers (TMs), especially carcinoembryonic antigen (CEA), and to determine whether TMs could guide adjuvant chemotherapy.
|
31614135 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Multivariate analysis of PC revealed that T4 cancer (OR 5.143, 95% CI 1.400-18.897, p = 0.014), T3 mucinous cancer (OR 17.480, 95% CI 1.577-193.714, p = 0.020), obstructed tumors (OR 6.030, 95% CI 1.627-22.343, p = 0.007), and peritoneal fluid CEA above 5 ng/dl (OR 4.073, 95% CI 1.315-12.615, p = 0.015) were significant risk factors.
|
31802190 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Four serum tumor markers (CEA, SCC, NSE, ProGRP) were examined simultaneously.
|
31424643 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Elevated levels of preoperative tumor markers (TMs), including carcinoembryonic antigen and carbohydrate antigen 19-9 are risk factors for the survival of patients with pancreatic cancer (PC).
|
31030989 |
2020 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Thirty-eight patients (35%) had tumors with high PGRN expression, and there was a trend of elevated pre-operative CEA and CA19-9 levels in patients with high PGRN-expressing tumors compared to those with low PGRN-expressing tumors (CEA, 49% vs. 21%; CA19-9, 21% vs. 7%).
|
30378010 |
2020 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The tumor showed aggressive behavior and serum CEA levels increased with repeated recurrence.
|
31828452 |
2020 |